AIM ImmunoTech Files 8-K
Ticker: AIM · Form: 8-K · Filed: Feb 7, 2025 · CIK: 946644
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
AIM ImmunoTech filed an 8-K on Feb 7, 2025. Standard corporate update.
AI Summary
AIM ImmunoTech Inc. filed an 8-K on February 7, 2025, reporting other events and financial statements. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and headquartered in Ocala, Florida.
Why It Matters
This filing provides an update on AIM ImmunoTech's corporate activities and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine corporate filing and does not appear to contain significant new information that would immediately impact the company's risk profile.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- Hemispherx Biopharma Inc. (company) — Former company name
- February 7, 2025 (date) — Date of report
- Ocala, Florida (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of February 7, 2025.
When was AIM ImmunoTech Inc. formerly known as?
AIM ImmunoTech Inc. was formerly known as HEMISPHERX BIOPHARMA INC.
In which state is AIM ImmunoTech Inc. incorporated?
AIM ImmunoTech Inc. is incorporated in Delaware.
What is the business address of AIM ImmunoTech Inc.?
The business address of AIM ImmunoTech Inc. is 2117 SW Highway 484, Ocala, FL 34473.
What is the SEC file number for AIM ImmunoTech Inc.?
The SEC file number for AIM ImmunoTech Inc. is 001-27072.
Filing Stats: 614 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-02-07 08:55:29
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 23KB
- 0001493152-25-005310.txt ( ) — 263KB
- aim-20250207.xsd (EX-101.SCH) — 3KB
- aim-20250207_lab.xml (EX-101.LAB) — 33KB
- aim-20250207_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: February 7, 2025 By /s/ Thomas K. Equels Thomas K. Equels, CEO -3-